Company Overview and News

17
Sally Beauty Grapples With Declining Comps & Margins

2018-07-11 zacks
Shares of Sally Beauty Holdings, Inc. (SBH - Free Report) have not only declined, but also underperformed the industry and the overall sector in the past three months. This Zacks Rank #4 (Sell) stock lost 1.1% against the industry’s growth of 13.7% and overall sector’s increase of 10.6%, courtesy of the decline in comps and contraction in margins. Apart from these, the trimmed guidance for fiscal 2018 also hurt investors’ sentiments.
SCVL SBH URBN FOSL

0
SBH / Sally Beauty Holdings, Inc. / BlackRock Inc. - null (Passive Investment)

2018-07-10 sec.gov
us79546e1047_070518.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 2) SALLY BEAUTY HOLDINGS INC -------------------------------------------------------- (Name of Issuer) Common Stock -------------------------------------------------------- (Title of Class of Securities) 79546E104 -------------------------------------------------------- (CUSIP Number) June 30, 2018 -------------------------------------------------------- (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) *The remainder of this co
SBH

0
SBH / Sally Beauty Holdings, Inc. / BlackRock Inc. - null (Passive Investment)

2018-07-10 sec.gov
us79546e1047_070518.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 2) SALLY BEAUTY HOLDINGS INC -------------------------------------------------------- (Name of Issuer) Common Stock -------------------------------------------------------- (Title of Class of Securities) 79546E104 -------------------------------------------------------- (CUSIP Number) June 30, 2018 -------------------------------------------------------- (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) *The remainder of this co
SBH

129
Top Analyst Upgrades and Downgrades: Citigroup, Oracle, PTC Therapeutics, Starbucks, Tableau Software, Williams-Sonoma and More

2018-06-20 247wallst
The futures traded higher Wednesday morning, and while concerns over the potential for a full-out trade war continue to trouble investors, buyers look ready to jump in. Despite the big losses in the Dow Jones industrial average, the S&P 500 and the Nasdaq, once again the Russell 2000 small cap index printed another all-time high on Tuesday. Clearly, investors look to be rotating to small cap stocks, as many do the bulk of their business in the United States and may face less pressure from potential tariffs.
WSM C.WSA DB MS.PRE MS.PRF MS.PRG MS.PRA C.WS.B C.WS.A C.PRP C.PRU MS ORCL C.PRS C C.PRL DATA C.PRJ C.PRK SBH C.PRG C.PRC MS.PRI C.PRPCL MS.PRK CGBBW OCLCF TRI SBUX MIME PTCT

13
Sally Beauty (SBH) Stock Falls Since Q2 Earnings: Here's Why

2018-06-18 zacks
Sally Beauty Holdings, Inc. (SBH - Free Report) has fallen 9.3% since its second-quarter fiscal 2018 earnings release. This is primarily due to the company’s earnings miss, after a beat in the preceding quarter. Further, decline in comps and contraction in margins also disappointed.
HD SBH

95
No Need to Panic About the Downgrade of Ulta Beauty Inc Stock

2018-06-06 investorplace
A big rally in Ulta Beauty Inc (NASDAQ:ULTA) has hit a couple of speed bumps in the past week — but it looks like Ulta Beauty stock will come out just fine.
JBK GS.PRICL GSC ULTA TFG GS.PRB GS.PRA ANF SBH GSJ GS.PRJ GS GS.PRI TSCO GLSSP GS.PRD GS.PRC AEO PRTY GJS GS.PRN GS.PRK

1
SBH / Sally Beauty Holdings, Inc. 8-K (Current Report)

2018-05-28 sec.gov
sbh-8k_20180523.htm
SBH

1
SBH / Sally Beauty Holdings, Inc. S-3ASR

2018-05-08 sec.gov
S-3ASR Table of Contents As filed with the Securities and Exchange Commission on May 8, 2018 Registration No. 333-
SBH

1
SBH / Sally Beauty Holdings, Inc. S-3ASR

2018-05-08 sec.gov
S-3ASR Table of Contents As filed with the Securities and Exchange Commission on May 8, 2018 Registration No. 333-
SBH

1
SBH / Sally Beauty Holdings, Inc. S-3ASR

2018-05-08 sec.gov
S-3ASR Table of Contents As filed with the Securities and Exchange Commission on May 8, 2018 Registration No. 333-
SBH

1
SBH / Sally Beauty Holdings, Inc. S-3ASR

2018-05-08 sec.gov
S-3ASR Table of Contents As filed with the Securities and Exchange Commission on May 8, 2018 Registration No. 333-
SBH

1
SBH / Sally Beauty Holdings, Inc. S-3ASR

2018-05-08 sec.gov
S-3ASR Table of Contents As filed with the Securities and Exchange Commission on May 8, 2018 Registration No. 333-
SBH

1
SBH / Sally Beauty Holdings, Inc. S-3ASR

2018-05-08 sec.gov
S-3ASR Table of Contents As filed with the Securities and Exchange Commission on May 8, 2018 Registration No. 333-
SBH

1
SBH / Sally Beauty Holdings, Inc. S-3ASR

2018-05-08 sec.gov
S-3ASR Table of Contents As filed with the Securities and Exchange Commission on May 8, 2018 Registration No. 333-
SBH

1
SBH / Sally Beauty Holdings, Inc. S-3ASR

2018-05-08 sec.gov
S-3ASR Table of Contents As filed with the Securities and Exchange Commission on May 8, 2018 Registration No. 333-
SBH

Related Articles

CATB: Catabasis Pharmaceuticals Analysis and Research Report

2018-07-13 - Asif

Overview Catabasis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics based on its proprietary Safely Metabolized And Rationally Targeted linker, or SMART LinkerSM, drug discovery platform. The company's SMART Linker drug discovery platform enables it to engineer product candidates that can simultaneously modulate multiple targets in a disease. The company's proprietary product candidates impact pathways that are central to diseases where efficacy may be optimized by a multiple target approach. Catabasis Pharmaceuticals has applied its SMART Linker drug discovery platform to build an internal pipeline of product candidates for rare diseases, its primary focus, and plan to pursue partnerships to develop additional product candidates. The company's lead product candidate is edasalonexent, formerly known as CAT-1004, which the company believe has the potential to be a disease-modifying...

WMT: Walmart Analysis and Research Report

2018-07-09 - Asif

Overview Walmart Inc. helps people around the world save money and live better – anytime and anywhere – in retail stores and through eCommerce. Through innovation, Walmart is striving to create a customer-centric experience that seamlessly integrates its eCommerce and retail stores in an omni-channel offering that saves time for its customers. Each week, the company serve nearly 270 million customers who visit its more than 11,700 stores and numerous eCommerce websites under 65 banners in 28 countries. The company's strategy is to lead on price, invest to differentiate on access, be competitive on assortment and deliver a great experience. Leading on price is designed to earn the trust of its customers every day by providing a broad assortment of quality merchandise and services at everyday low prices ("EDLP"). EDLP is its pricing philosophy under which the company price items at a low price every day so its customers trust that its prices will not change under frequent prom...

NVRO: Nevro Corp Analysis and Research Report

2018-07-06 - Asif

Overview Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from chronic pain. Nevro has developed and commercialized the Senza® spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain. The company's proprietary paresthesia-free HF10TM therapy, delivered by its Senza system, was demonstrated in its SENZA-RCT study to be superior to traditional SCS therapy with it being nearly twice as successful in treating back pain and 1.5 times as successful in treating leg pain when compared to traditional SCS therapy. Comparatively, traditional SCS therapy has limited efficacy in treating back pain and is used primarily for treating leg pain, limiting its market adoption. The company's SENZA-RCT study, along with its European studies, represents what the company believe is the most robust body of clinical evidence for any SCS therapy. The compa...

Silicon Investor Message Boards

This table lists all message boards related to SBH / Sally Beauty Holdings, Inc. on message board site Silicon Investor.

Smithkline Beecham (SBH)
CUSIP: 79546E104